Intra Cellular Buy or Sell Recommendation

Macroaxis provides Intra Cellular Therapies Inc buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Intra Cellular positions. The advice algorithm takes into account all of Intra Cellular Therapies Inc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Intra Cellular buy-and-hold prospective. Please also check Intra Cellular Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Investment Horizon


Risk Tolerance

Execute Advice
Intra Cellular Therapies Inc -- USA Stock  

USD 15.99  0.03  0.19%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Intra Cellular Therapies Inc is 'Cautious Hold'.
For the selected time horizon Intra Cellular Therapies Inc has a mean deviation of 2.36, semi deviation of 0.0, standard deviation of 3.71, variance of 13.77, downside variance of 0.0 and semi variance of 0.0
This buy, hold, or sell suggestion tool can be used to cross verify current analyst consensus on Intra Cellular and to analyze the organization potential to grow in the current economic cycle. To make sure Intra Cellular Therapies Inc is not overpriced, please check out all Intra Cellular fundamentals including its Net Income, Earnings Per Share, Current Liabilities, as well as the relationship between Current Ratio and Total Asset . Given that Intra Cellular Thera has Price to Earning of (6.73) times, we strongly advise you confirm Intra Cellular Thera market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Returns Distribution Density

Mean Return-0.99Value At Risk-7.2629
Potential Upside2.6439Standard Deviation3.7102
 Return Density 

Intra Cellular Greeks

Alpha over DOW
βBeta against DOW= 4.2 
Overall volatility
= 3.63 
 IrInformation ratio =(0.3) 

Intra Cellular Volatility Alert

Intra Cellular Therapies Inc exhibits very low volatility with skewness of -1.88 and kurtosis of 5.43. However, we advise investors to further study Intra Cellular Therapies Inc technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare Intra Cellular to competition
FundamentalsIntra CellularPeer Average
Return On Equity(26.76) % (15.17) %
Return On Asset(16.4) % (15.64) %
Current Valuation342.61 M152.14 B
Shares Outstanding53.1 M1.43 B
Shares Owned by Insiders12.68 % 6.91 %
Shares Owned by Institutions68.01 % 18.37 %
Number of Shares Shorted5.92 M3.24 M
Price to Earning(6.73) times40.69 times
Price to Book2.03 times14.44 times
Revenue312.29 K9.85 B
Gross Profit330.7 K21.75 B
EBITDA(104.39 M)1.41 B
Net Income(102.44 M)517.71 M
Cash and Equivalents342.63 M3.89 B
Cash per Share7.89 times5.17 times
Debt to Equity0.31 % 0.72 %
Current Ratio50.1 times3.3 times
Book Value Per Share7.82 times13.64 times
Cash Flow from Operations(99.39 M)1.25 B
Short Ratio22.2 times2.09 times
Earnings Per Share(2.36) times2.3 times
Number of Employees3710.67 K
Market Capitalization844.32 M29.78 B
Total Asset542.57 M126.86 B
Retained Earnings(193.05 M)38.24 B
Working Capital401.13 M3.58 B
Current Asset541.82 M36.8 B
Current Liabilities140.69 M33.34 B
Cautious Hold

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

   Bona fide gift to Richard Lerner of 20000 shares of Intra Cellular subject to Section 16 [view details]
Risk Adjusted Performance(0.051341)
Market Risk Adjusted Performance(0.23)
Mean Deviation2.36
Coefficient Of Variation(376.67)
Standard Deviation3.71
Information Ratio(0.3)
Jensen Alpha(1.52)
Total Risk Alpha(3.01)
Treynor Ratio(0.24)
Maximum Drawdown16.01
Value At Risk(7.26)
Potential Upside2.64

Current Valuation

Intra Cellular Current Valuation Analysis
Intra Cellular Therapies Inc is considered the number one company in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 1.22 Billion. Intra Cellular totals roughly 342.61 Million in current valuation claiming about 28% of stocks in Biotechnology industry.